The Role of MAPK-Signalling in Pancreatic Neuroendocrine Cancer Abstract #1737

Introduction: Upon diagnosis, 65% of pNET patients suffer from metastatic or locally unresectable disease. The receptor tyrosine kinase inhibitor sunitinib and the mTOR inhibitor everolimus have set precedence for successful targeted therapies in pNET disease. However, response prediction and treatment alternatives still do not meet medical needs. Recent studies revealed mutations in RAS oncogenes in a fraction of tumours, emphasising a potential role of the MAPK pathway as therapeutic target.
Aim(s): To study the consequences of pharmacologic inactivation of MEK or ERK kinases in pNET cells.
Materials and methods: BON-1 and QGP-1 cell lines are treated with either MEK or ERK inhibitors. Live cell analysis is performed to determine efficacy and growth inhibition. Induction of apoptosis is shown by cleaved caspase-3 and cell cycle regulation is analysed by flow cytometry. Changes in the MAPK and mTOR signalling network are determined by western blots and multiplex immunoassays.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Julia Hoffmann

To read results and conclusion, please login ...

Further abstracts you may be interested in

#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Sara Massironi
#16 Endoglin as indicator of metastatic neuroendocrine tumors of the pancreas
Introduction: Neuroendocrine tumors of the pancreas are rare, highly vascularized tumors. Endoglin, a Transforming Growth Factor-β co-receptor, is a marker for angiogenic endothelial cells. Angiogenesis is required for tumor progression and the development of metastases. Recently, endoglin expression was found to be a prognostic marker in pancreatic carcinomas. However, the role of endoglin in neuroendocrine pancreatic tumors has so far not been studied.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Patricia Kuiper
#38 Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors
Introduction: Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Professor Hironobu Sasano
Authors: Iida S, Miki Y, Ono K, Sasano H, ...
#61 Multiple tumors in patients with pancreatic neuroendocrine tumours: morphological and immunohistochemical characteristics
Introduction: Pancreatic islet cell tumors occur in 80% of patients with MEN 1. Tumors are often multicentric. They often produce multiple peptides and biogenic amines.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Prof Larisa Gurevich
#62 Genome-wide DNA methylation profiling of pancreatic neuroendocrine tumors identifies distinct methylation profiles and differentially methylated gene promoter regions associated with low, medium and high grade tumors
Introduction: Integration of genetics and epigenetics has emerged as a powerful approach to studying cellular differentiation (Mikkelsen et al, 2009) and tumorigenesis (Shen et al, 2007). The study of DNA methylation is of particular importance in cancer, as causal involvement has been demonstrated and it is the most stable of all epigenetic modifications, making it a desirable marker for both early detection and treatment of tumors. Hypermethylation of CpG sites in gene promoter regions leads to decreased gene expression; if such a gene is a tumor suppressor, this leads to carcinogenesis. To date, there have been no studies of genome-wide DNA methylation profiling of NETs. This study sets out to determine the DNA methylation profiles of low, intermediate and high grade pancreatic NET liver metastases with the intention of identifying dysregulated biological pathways in the development of these tumors. A protocol for the analysis formalin-fixed paraffin embedded tissue (FFPE) has also been developed in order to study these tumors in significant numbers following this pilot study.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Christina Thirlwell
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.